Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Down but not out for TC-5214 in depression

This article was originally published in Scrip

Executive Summary

AstraZeneca/Targacept's investigational antidepressant TC-5214 has failed its first Phase III trial, which tested whether the antidepressant is effective as an add-on to existing treatments in non-responders. Despite the obvious setback, especially for Targacept which lost around $350 million in market value on the announcement of the failure, AstraZeneca and Targacept should remain optimistic for TC-5214's remaining Phase III studies. It can be notoriously difficult to demonstrate a significant effect in depression trials due to high placebo responses.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts